Apollo Hospitals Enterprise Limited (APOLLOHOSP) — Board Meeting | 6 November 2025

· NSE 🟡 Notable ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Apollo Hospitals reported H1 FY26 consolidated revenue of ₹12,146 crores with 14% YoY growth, PAT of ₹910 crores (33% growth), and diluted EPS of ₹33.19. The board approved a Composite Scheme of Arrangement to demerge omni-channel pharmacy and digital health businesses into Apollo Healthtech Limited, with CCI approval received on September 23, 2025. Healthcare Services segment grew 9% to ₹3,169 crores with 24.6% EBITDA margins. The company acquired remaining 50% stake in Apollo Gleneagles PET-CT, making it wholly-owned.

📄 View Original Announcement (PDF)

About Apollo Hospitals Enterprise Limited (APOLLOHOSP)

Healthcare · Healthcare Services · Listed on NSE

Market Cap: ₹1,16,213.95 Cr P/E: 64.5 ROE: 21.9% ROCE: 20.5%

View full APOLLOHOSP stock details →

📡 Get AI alerts when APOLLOHOSP files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track APOLLOHOSP — Free

📊 More APOLLOHOSP filings

See all APOLLOHOSP filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when APOLLOHOSP files new disclosures

Track APOLLOHOSP filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track APOLLOHOSP — Free

Free account · 2 AI queries/day